PNC Financial Services Group
COCP icon

PNC Financial Services Group’s Cocrystal Pharma COCP Stock Holding History

PNC Financial Services Group’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18
Closed -$36 – 4709
2022
Q4 		$36 Buy
+18
New +$46 ﹤0.01% 4727

Other funds holding COCP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PNC Financial Services Group's COCP Position: Q1 2023 in Review

PNC Financial Services Group sold out of Cocrystal Pharma (COCP) in Q1 2023, closing a stake of 18 shares — an estimated $36 sold.

PNC Financial Services Group first reported a position in COCP in Q4 2022 and held it in 1 quarter. The position peaked at $36 in Q4 2022. 21 funds tracked by Wall St. Rank hold COCP as of Q1 2023.

  • PNC Financial Services Group reported no remaining Cocrystal Pharma position as of Q1 2023 after selling out during the quarter.
  • PNC Financial Services Group sold 18 Cocrystal Pharma shares in Q1 2023, an estimated $36.
  • PNC Financial Services Group first reported a position in Cocrystal Pharma in Q4 2022 and held it in 1 quarter.
  • PNC Financial Services Group's Cocrystal Pharma position peaked at $36 in Q4 2022.
  • 21 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q1 2023.

Based on PNC Financial Services Group's 13F filing for Q1 2023, filed 15 May 2023.